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CHOPSummary Although diffuse large B-cell lymphoma (DLBCL) encompasses a biologically and clinically
diverse set of diseases, increasing evidence has pointed to an important role of microRNAs (miRs) in the
pathogenesis of DLBCL. We report here that low expression of miR-146b-5p and miR-320d is
associated with poor prognosis of DLBCL patients treated with the standard cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) regimen and that this is related to the inhibitory effect
of these miRs on DLBCL cell proliferation. Analysis of a retrospective cohort of 106 primary nodal
DLBCL samples from patients who were treated with CHOP showed that, when the median survival
period (40.8 months) was used as the cutoff point, miR-146b-5p and miR-320d were expressed at lower
levels in DLBCLs with poor prognosis. Indeed, whereas low expression of miR-146b-5p was correlated
with reduced progression-free survival, low expression of miR-320d was associated with decreases in
both progression-free survival and overall survival. Moreover, miR-146b-5p and miR-320d were
expressed at significantly lower levels in DLBCLs with the MYC t(8;14) translocation. Functional
studies demonstrated that overexpression of miR-146b-5p or miR-320d inhibited DLBCL cell
proliferation, wheareas knockdown of miR-146b-5p or miR-320d promoted proliferation of DLBCL
cells. Taken together, these results suggest that low expression of miR-146b-5p and miR-320d may be
predictive of compromised responses of a subset of DLBCL patients to treatment with the CHOP
regimen and that restoration of these miRs may be useful to improve the therapeutic efficacy of CHOP.
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046-8177/© 2014 Published by Elsevier Inc.1. IntroductionDiffuse large B-cell lymphoma (DLBCL) is the most
common type of non-Hodgkin lymphoma in adults [1,2].
However, approximately half of DLBCL patients cannot be
Table 1 Summary of DLBCL patients
Characteristic No. 5-y
OS(%)
P a 5-y PFS(%) P a
Age, y
b60 65 37.8 37.0
≥60 41 31.0 .68 30.2 .716
Sex
Male 68 33.8 33.6
Female 38 42.0 .301 37.9 .335
Phenotype
1665miR-146b-5p and miR-320d in DLBCLcured with the standard cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) regimen or the rituxi-
mab plus CHOP (R-CHOP) regimen [3,4]. This is closely
associated with the heterogeneity of DLBCLs both biologi-
cally and clinically [5]. DLBCLs can be divided into at least 2
subgroups: germinal center B-cell (GCB) type and nongerm-
inal centerlike (non-GCB) type; yet even within each
subgroup, there are still wild variations in molecular
characteristics [6]. Apart from the International Prognostic
Index (IPI) [7], there is currently no consensus on biomarkers
predictive of responses of DLBCL patients to treatment.
Further understanding of molecular mechanisms responsible
for the heterogeneity of DLBCLs is therefore urgently needed.
MicroRNAs (miRs) regulate gene expression in a
sequence specific manner through binding to 3’UTRs of
mRNAs, either targeting the transcripts for degradation or
blocking their translation [8,9]. MiRs can potentially affect
multiple steps of the pathogenesis of cancer by regulating a
variety of target genes. In DLBCL, a number of miRs have
been demonstrated to play roles in the disease development,
progression, and responses to treatment [10]. In particular,
miR-21 regulates the sensitivity of DLBCL cells to the
CHOP regimen [11], whereas miR-181a and miR-222 have
been proposed to be independent predictors of the outcome
of DLBCL patients in response to treatment with R-CHOP
[12]. Moreover, the increased expression of miR-155 in
DLBCL cells may have a diagnostic value; and elevated
miR-34a may be of prognostic significance [13,14].
In this study, we have examined the expression of miRs in
a cohort of DLBCL samples from 106 patients with varying
clinicopathological characteristics who were treated with the
CHOP regimen. We report here that miR-146b-5p and miR-
320d are expressed at lower levels in DLBCL patients with
poor prognosis and that low expression of these miRs is an
independent predictor of compromised responses of DLBCL
patients to treatment with CHOP. In addition, we show that
both miR-146b-5p and miR-320d have an inhibitory effect
on DLBCL cell proliferation.GCB 47 46.8 44.4
Non-GCB 59 29.0 .017 29.1 .019
B symptoms
Present 55 34.8 35.3
No 51 36.9 .344 36.8 .383
Stage
I-II 45 44.4 41.9
III-IV 61 31.4 .048 31.5 .053
Extranodal
involvement
b2 101 18.6 42.4
≥2 5 .489 28.6 .472
LDH
Normal 53 38.5 39.3
High 53 33.1 .065 32.6 .067
IPI score
b3 60 39.7 39.1
≥3 46 33.5 .051 31.9 .049
a P b .05 was considered statistically significant.2. Materials and methods
2.1. Patients
A retrospective cohort of 106 primary nodal DLBCL
samples from patients who attended the Department of
Hematology of Shanxi Cancer Hospital and underwent the
treatment with the CHOP regimen between 2001 and 2010 was
recruited into this study. The patients were followed up
quarterly for the first year, semiannually for the next 2 years,
and annually thereafter. Detailed clinicopathological informa-
tion of these patients is shown in Table 1. All the DLBCL
samples were reviewed for diagnostic accuracy by 2 indepen-
dent pathologists. Thirty reactive hyperplasia lymph node
tissues were also obtained from the Department of Hematologyof Shanxi Cancer Hospital that were used as controls. The study
was approved by the Medical Ethics Committee of Shanxi
Province CancerHospital. Informed consent was obtained from
each patient at the time of the first visit according to the
Declaration of Helsinki [15].
2.2. Cell culture and reagents
HumanDLBCL cell lines were kindly provided by professor
Jiang Zhu (Ruijin Hospital, Shanghai Jiao Tong University
School of Medicine), professor Tong Zhao (Nanfang Medical
University), and professor XiaoYan Zhou (Cancer Hospital,
Shanghai FudanUniversity), includingDB, SUDHL-4, RJ-Ly2,
OCI-Ly1, and OCI-Ly8 (GCB type), and RJ-Ly1 and OCI-
Ly10 (activated B-cell-like, ABC type). They were cultured in
RPMI-1640medium (HyClone, Logan,UT) supplementedwith
15% fetal bovine serum (Gibco, Carlsbad, CA) at 37°C in a
humidified air atmosphere containing 5% CO2.
2.3. Immunohistochemistry and fluorescence in
situ hybridization analysis
Immunohistochemical staining was performed on forma-
lin-fixed, paraffin-embedded (FFPE) tissue sections using
the EnVision method for CD3, CD10, CD20, Bcl-6, and
1666 P. Y. Wu et al.MUM-1 (Maixin-Bio, Fuzhou, China). According to Hans’
algorithm, all patients were assigned to the GCB or non-GCB
group [16]. Interphase fluorescence in situ hybridization was
also performed on FFPE tissues to detect translocations of the
MYC gene using break-apart assays for MYC and the dual-
color, dual-fusion translocation probes LSI MYC/IGH (from
Abbott/Vysis, Downers Grove, IL). Briefly, after overnight
hybridization and subsequent washing, the slides were
analyzed using a Leica TCS SP5 Laser Scanning Confocal
Microscope (Leica, Wetzlar, Germany).
2.4. Cell proliferation and apoptosis
Cell Counting Kit–8 (CCK-8, Dojindo, Kumamoto, Japan)
was used to determine the number of viable cells. Briefly, cells
were plated onto 96-well plates (1 × 104 cells per well).
Quantitation of apoptotic cells was carried out usingAnnexinV/
7-amino-actinomycin D staining according to the manufac-
turer’s instruction (KeyGEN, Nanjing, China). Stained samples
were analyzed using a FACscan flow cytometer (Becton
Dickinson, San Jose, CA) equipped with FlowJo software.
2.5. MiRNA expression profiling
MiR expression profiling was carried out using the Agilent
Human miR Microarray 16.0 (CapitalBio, Beijing, China)
according to the manufacturer’s instruction. This array contains
15,024 probes and can recognize 939 miRs. Total RNA was
extracted using a miR isolation kit (Ambion). Fluorescein-
labeled miRs were used for hybridization on each miR
microarray chip. The chips were scanned using ScanArray
Express laser scanner (Packard Bioscience, Covina, CA), and
the images were analyzed using LuxScan 3.0 software
(CapitalBio). The filtered results were subject to cluster software
(Cluster 3.0) and TreeView analysis (Stanford University) for
unsupervised hierarchical clustering by genes and arrays.Metric
(distance) and linkage were set as Euclidean distance and
average, respectively.
2.6. Quantitative reverse transcriptase polymerase
chain reaction
Quantitation of the expression of miR-320d and miR-
146b-5p by quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR) was carried out using the TaqMan
MicroRNA Assays kit (Applied Biosystems) according to
the manufacturer’s instructions. Five microliters of total
RNA from each sample was reverse transcribed using the
TaqMan MicroRNA Reverse Transcription kit (Applied
Biosystems). qRT-PCR were carried out in final volumes of
10 μL using the ABI Sequence Detection System Instrument
and software (Applied Biosystems). Amplifications were
initiated with 10-minute incubation at 95°C followed by 40
cycles at 95°C for 15 seconds and 60°C for 60 seconds. To
normalize the expression levels of miRs, we used U6 RNA asan internal control. qRT-PCR was performed in triplicate,
including no-template controls. The relative expression of
each miR was calculated from the following equation:
relative expression = 2−ΔCt, where Ct is the threshold cycle
for a sample and ΔCt = (CtmiRNA)mean − (CtU6)mean.
2.7. Lentiviral transduction
The expression plasmids for miR-146b-5p and miR-
320d were created by PCR amplification with human
genomic DNA as templates. The primers are as follows:
hsa-miR-320d: 5′-GGGCCCGCTCTAGACTCGAGA-
TATTTGCATGTCGCTATGTG-3′, hsa-miR-146b-5p:
5 ′ -GGGCCCGCTCTAGACTCGAGATATTTG-
CATGTCGCTATGTG-3′, and hsa-miR-146b-5p shRNA:
5′-AGCCTATGGAATTCAGTTCTCA-3′. The PCR product
of miR-146b-5p and miR-320d was cloned into GV259 vector
carrying the green fluorescent protein (GFP) gene (pGV259-
GFP, Genechem, Shanghai, China). A universal sequence
(PSC-NC: TTCTCCGAACGTGTCACGT) was used as a
negative control for RNA interference. All constructs were
confirmed by DNA sequencing. To produce lentivirus, these 3
plasmid DNAs were individually transferred into 293 T cells
using pHelper1.0, pHelper2.0 packaging construct, and
Lipofectamine Plus reagent (Invitrogen) according to the
manufacturer’s protocol. For transduction assay, OCI-Ly8, DB,
and OCI-Ly10 were seeded into 24-well plates (1 × 105cells per
well) and transduced with different lentiviral vectors at a
multiplicity of infection of 50. Three days after transduction,
GFP expression was detected to calculate the transduction
efficiency by fluorescence-activated cell sorting (FACs). Five
days after transduction, FACs-sorted GFP+ transduced cells
were diluted to 10,000 cells per milliliter; and about 3000 cells
(0.3mL)were plated on 6 Petri dishes (10 cm) inwhich colonies
were scored at 7 and 15 days. qRT-PCR was performed to
determine miR-146b-5p and miR-320d efficiency.2.8. Statistics
The miR genes showing significant expression changes
(1.5-fold change) and false discovery rate = 0 were considered
to be significantly expressed in different prognostic samples.
The Mann-Whitney test was used to analyze the differences in
miR expression between the patients and controls. Up- and
downregulation groupswere based onmiR expression below or
above the corresponding median. Survival curves were
estimated using the product-limit method of Kaplan-Meier
and were compared using the log-rank test. Univariate and
multivariate analyses were performed. Multivariate regression
analysis according to the Cox proportional hazards regression
model, with overall survival (OS) or progression-free survival
(PFS) as the dependent variables, was used to adjust for the
effects of the miRs expression. Student t test was used to
compare test groups with negative control ones.P value of b.05
was considered to be statistically significant.
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3.1. MiR-146b-5p and miR-320d are downregulated
in DLBCLs from patients with poor prognosis
A retrospective cohort of primary nodal DLBCLs from 106
patients who attended the Department of Hematology at
Shanxi Cancer Hospital between 2001 and 2010 was included
in this study. The clinicopathological characteristics of these
DLBCLs and patients are summarized in Table 1. The median
OS of the patients after treatment with the standard CHOP
regimen was 40.8 months. Among the DLBCLs, 47 were the
GCB type (44.3%); and the remaining 59, the non-GCB type
(55.7%) (Fig. 1A). Whereas 15 DLBCLs of the non-GCB type
displayed the t(8;14)MYC translocation, this was not detected
in those of the GCB type (Fig. 1B).
We initially compared miR expression profiles between
randomly sampled, treatment-naive DLBCLs from 6 patients
who survived longer (≥40.8 mo, median OS) and those from
another 6 patients with shorter survival (b40.8 mo) using a
Human miRNA Microarray Kit that contains 15,024 probes
and recognizes 939 miRNAs. The results showed that 29
miRNAs were differentially expressed in DLBCLs from
patients who had bad prognosis (b40.8 mo) compared to those
from patients with good prognosis (≥40.8 mo) (Fig. 2A).
Among them were miR-146b-5p and miR-320d that were
decreased on average 2.91- and 1.76-fold, respectively.
Downregulation of these miRs was subsequently confirmed
by use of qRT-PCR in the whole cohort of 106 DLBCLs. Of
note, miR-146b-5p and miR-320d were in general expressed at
lower levels in DLBCL tissues than the control lymph nodes
(Fig. 2B). In addition, they appeared to be reduced in DLBCLs
of the non-GCB type, in particular, in those with the MYC t
(8;14) translocation (Table 2).
3.2. Low expression of miR-146b-5p and miR-320d
predicts compromised responses of DLBCLs to
treatment with CHOP
Because all the patients in this cohort were solely treated
with the standard CHOP regimen, the finding of downreg-
ulation of miR-146b-5p and miR-320d in DLBCLs from
patients with poor prognosis suggests that the levels of these
miRs may be predictive of responses of DLBCLs to
treatment with CHOP. We confirmed this by analyzing the
relationship between the levels of miR-146b-5p and miR-
320d and OS and PFS of the patients. As shown in Fig. 3A,
low expression of miR-146b-5p (b1.87, median expression
level) was associated with reduced PFS; and low expression
of miR-320d (b1.97, median expression level) was associ-
ated with reduction in both OS and PFS. Patients with low
expression of miR-146b-5p had a median PFS of 9.4 months
compared to those with high expression of the miR (≥1.87),
who had a median PFS of 35.5 months. Similarly, patients
with low expression of miR-320d had a median PFS and OSof 6.7 months and 15.4 months, respectively, compared to
those with high expression of the miR, who had a median
PFS of 36 months and a median OS of 43 months. As
expected, patients with DLBCLs that displayed the MYC
t(8;14) translocation had markedly shorter OS and PFS.
When assessed by the multivariate analysis, it appeared that
the reduced expression of miR-320d was an independent
predictor ofOS relative to other clinicopathological parameters
such as IPI, serum lactate dehydrogenase (LDH) levels, the
presence of B symptoms, and Arbor stages (Table 3). In
addition, the decrease in miR-320d or miR-146b-5p was an
independent predictor of PFS (Table 3). Taken together, these
results suggest that reduction in the expression of miR-146b-
5p and/or miR-320d may be a useful biomarker to predict
compromised responses of DLBCLs to treatment with the
standard CHOP regimen.
3.3. MiR-146b-5p andmiR-320d inhibit proliferation
of DLBCL cells
We also examined the expression of miR-146b-5p and
miR-320d in a panel of DLBCL cell lines by qRT-PCR.
The levels of miR-320d were markedly lower in DLBCL
cell lines of the ABC type than those of the GCB type.
Whereas the miR-146b-5p level was 10 times lower
in DB cells than OCI-Ly8 cells, the level of miR-320d
in OCI-Ly10 cells was reduced approximately 4 times
compared with OCI-Ly8 cells (Fig. 4A).
To determine the functional significance of miR-146b-5p
and miR-320d in DLBCL cell survival and proliferation, we
introduced exogenous miR-146b-5p or miR-320d into OCI-
Ly10 and DB cells by lentiviral transduction (Fig. 4C). The
levels of miR-146b-5p and miR-320d in DLBCL cells
transduced with the miR-expressing constructs were markedly
higher than those transduced with the control constructs (Fig.4
B). Overexpresssion of either miR-146b-5p or miR-320d
significantly inhibited proliferation of both OCI-Ly10 and
DB cells (Fig. 4D). This was associated with induction of
moderate levels of apoptosis. In contrast, lentiviral trans-
duction of miR-146b-5p shRNA into OCI-Ly8 cells
enhanced cell proliferation (Fig. 4D). These results indicate
that miR-146b-5p and miR-320d play a role in inhibiting
DLBCL cell proliferation.4. Discussion
In this report, we present evidence that miR-146b-5p and
miR-320d are expressed at lower levels in DLBCLs from
patients with relatively poor prognosis and that low
expression of these miRs is an independent predictor of
compromised responses of the patients to treatment with the
standard CHOP regimen. In addition, we show that both
miR-146b-5p and miR-320d have an inhibitory effect on
proliferation of DLBCL cells.
Fig. 1 Differentaition of DLBCLs of the GCB type versus those of the non-GCB type and identification of the t(8;14) MYC translocation.
A, Representative microphotographs of immunohistochemistry staining of CD20, CD10, Bcl-6, and MUM-1 on DLBCL tissue sections. Scale
bar, 100 μm. B, Representative fluorescence in situ hybridization images obtained using an LSI MYCDual-Color Break-Apart Rearrangement
Probe to detect the t(8;14) MYC translocation. Left panel: nuclei of DLBCL cells without MYC translocation showing fusion signals (yellow
signals). Right panel: DLBCL cells with the t(8;14) MYC translocation. Separation of red and green signals was frequently observed in
individual nuclei. Scale bar, 5 μm.
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therapy has transformed DLBCL from a fatal malignancy to
a potentially curable disease, there are wild variations in
responses of DLBCL patients to treatment. Virtually only
fewer than half of patients can be cured [17]. This is closely
related to the molecularly heterogeneous nature of DLBCL
cells [18]. Although there is a large body of evidence
showing that deregulated expression of miRs contributes
significantly to the heterogeneity of DLBCLs, reports on the
potential role of miRs in regulating sensitivity of DLBCLs to
treatment with CHOP remain sparse [13], although miR-21
has been shown to regulate sensitivity of DLBCL cells to the
regimen [11]. Our finding that low expression of miR-146b-
5p and miR-320d is associated with poor prognosis of
DLBCL patients treated with CHOP irrespective of other
well-established clinicopathological parameters, such as IPI,
serum LDH levels, the presence of B symptoms, and Arbor
stages, strongly suggests that downregulation of these miRs is
a potential predictive biomarker of compromised responses of
DLBCLpatients to the CHOP regimen.However, whether low
expression ofmiR-146b-5p andmiR-320d is also predictive ofresponses ofDLBCL patients to other treatment protocols such
as R-CHOP remains to be studied.
The impact of reduction in miR-146b-5p and miR-320d
responses of DLBCL patients to CHOP is associated with the
ability of these miRs to inhibit proliferation of DLBCL cells.
This was demonstrated by decelerated proliferation of
DLBCL cells when miR-146b-5p or miR-320d was over-
expressed. In contrast, knockdown of either of the miRs
resulted in increased proliferation of DLBCL cells. However,
the exact molecular mechanisms by which these miRs inhibit
DLBCL cell proliferation are unknown. This is unlikely due
to induction of apoptosis in that overexpression of miR-
146b-5p or miR-320d did not trigger significant apoptotic
cell death. One possibility is that these miRs, like many
others, may regulate key components of signaling pathways
that control cell proliferation. For example, miR-125a and
miR-125b modulate activation of NF-kB; and miR-155
regulates the PI3K/Akt pathway, thus affecting DLBCL cell
proliferation [19,20]. MiR-320a has also been identified as a
critical component of the PTEN tumor suppressor axis in
stromal fibroblasts [21]. In addition, low expression of miR-
Fig. 2 MiR-146b-5p and miR-320d are frequently downregulated in DLBCLs from patients with poor prognosis (less than the median OS
40.8 months of the 106 DLBCL patients recruited into this study). A, Unsupervised hierarchical cluster analysis of filtered miRs that are
differentially expressed among DLBCL patients with shorter and longer survival. Yellow denotes high expression and blue denotes low
expression relative to the median. The metric was set as the Euclidean distance. B, Confirmation of frequent downregulation of miR-146b-5p
(upper panel) and miR-320d (lower panel) in 106 FFPE samples by qRT-PCR.Thirty reactive hyperplasia lymph node tissues were included as
controls. The average level of miR-146b-5p or miR-320d in reactive hyperplasia lymph nodes was arbitrarily designated as 1. The data shown
were mean ± SE of 3 individual experiments (*P b .01, Mann-Whitney independent t test).
1669miR-146b-5p and miR-320d in DLBCL320d is known to correlate with recurrence-free survival of
stage II colon cancer patients [22]. Although our results
clearly indicated that miR-146b-5p inhibited DLBCL cell
proliferation, a recent study has pointed to an oncogenic role
of miR-146b-5p in normal and transformed thyroid cells by
regulation of SMAD4 [23]. On the other hand, miR-146b-5pTable 2 MiR-146b-5p and miR-320d are differently expressed in DLBC
MYC translocation versus those of without t(8;14) MYC translocation
miRNA GCB/non-GCB a P b
miR-146b-5p 1.816/2.246 .079
miR-320d 0.960/2.393 .016
a GCB/non-GCB: the median expression level of miR in GCB/the median e
b P value b .05 was considered statistically significant.
c MYC translocation +/−: the median expression level of miR with MYC trancan inhibit glioma migration and invasion by targeting
matrix metalloproteinase 16 [24]. These findings, along with
ours, suggest that miR-146b-5p may have contrasting effects
on cell proliferation in a cell type–dependent manner.
Another possibility is that miR-146b-5p or miR-320d may
directly regulate the expression of cell cycle regulators suchLs of GCB type versus those of the non-GCB type and with t(8;14)
MYC translocation +/− c P b
0.370/2.000 .020
0.298/2.856 .018
xpression level of miR in non-GCB group.
slocation/the median expression level of miR without MYC translocation.
Fig. 3 Reduction in miR-146b-5p or miR-320d expression or the MYC t(8;14) translocation is associated with compromised responses of
DLBCL patients to treatment with CHOP. A, Kaplan-Meier analysis using the median abundance of miR-146b-5p as the cutoff showing that
low expression of the miR is associated with shorter OS (upper panel) and PFS (lower panel) of DLBCL patients after treatment with CHOP. B,
Kaplan-Meier analysis using the median abundance of miR-320d as the cutoff showing that low expression of the miR is significantly
associated with shorter OS (upper panel) and PFS (lower panel) of DLBCL patients after treatment with CHOP. C, Kaplan-Meier analysis
showing that patients with DLBCLs with the MYC t(8;14) translocation had shorter OS (left panel) and PFS (right panel).
Table 3 The low expression of miR-146b-5p and miR-320d is an independent predictor of DLBCL except the low expression of miR-
146b-5p for OS
Variable Risk
factor
OS PFS
Hazards ratio (95% CI) P a Hazards ratio (95% CI) P a
Sex Male 1.237 (0.709-2.157) .453 1.198 (0.688-2.086) .523
B symptoms Present 1.038 (0.618-1.743) .889 0.996 (0.559-1.678) .989
LDH NNormal 1.338 (0.791-2.264) .277 1.293 (0.765-2.184) .338
Stage III/IV 0.743 (0.255-2.170) .587 0.734 (0.243-2.220) .584
IPI ≥3 1.224 (0.683-2.192) .497 1.274 (0.714-2.272) .412
miR-146b-5p bM 1.267 (0.756-2.123) .37 1.851 (0.301-2.456) .046
miR-320d bM 2.002 (1.186-3.382) .009 2.225 (1.316-3.762) .003
Type non-GCB 2.303 (0.797-6.654) .123 2.409 (0.807-7.195) .115
Abbreviation: M, the median expression level of miR; OS, overall survival; PFS, progression-free survival; CI, confidence interval.
a P value b .05 was considered statistically significant.
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Fig. 4 MiR-146b-5p and miR-320d inhibit proliferation of DLBCL cells. A, left panel: relative abundance of miR-146b-5p in 7 DLBCL cell
lines as measured by qRT-PCR. The relative abundance of the miR expression in DB cells was arbitrarily designated as 1. Right panel: relative
abundance of miR-320d in 7 DLBCL cell lines was measured by qRT-PCR. The relative abundance of the miR expression in DB cells was
arbitrarily designated as 1. The expression of miR-320d was downregulated in DLBCL cell lines of the ABC type than those of the GCB type
(*P b .05). B, Overexpression of miR-146b-5p (left panel) and miR-320d (right panel) in DB and OCl-Ly10 cells, respectively. The data
shown were mean ± SE of 3 individual experiments (*P b .05). C, Representative microphotographs of DB, OCI-Ly8, and OCI-Ly10 cells
transduced with miR-146b-5p–expressing constructs, miR-146b-5p shRNA, and miR-146b-5p–expressing constructs, respectively, that were
enriched by FACscan sorting. Scale bar, 100 μm. D, DB (upper panel), OCI-Ly8 (middle panel), and OCI-Ly10 cells (lower panel) were
respectively transduced with miR-146b-5p–expressing constructs, miR-146b-5p shRNA, and miR-146b-5p–expressing constructs. Cell
proliferation was measured using Cell Counting Kit–8 assays at indicated time points after transduction. The data shown were mean ± SE of 3
individual experiments (*P b .05; **P b .01).
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1672 P. Y. Wu et al.as p21 and p27 [25]. A large number of miRs, such as miR-
224, miR-17, miR-663, and miR-221, are known to play a role
in regulating cell proliferation through modulating the
expression of key regulators of cell cycle progression [26–28].
An interesting finding of this study is that miR-146b-5p
and miR-320d are expressed at significantly lower levels in
DLBCLs with the MYC t(8;14) translocation. Whether there
is a causal relationship between downregulation of these
miRs and the MYC translocation needs to be further
investigated. Deregulated MYC is known to be a poor
prognostic factor in DLBCL patients [29]. The MYC protein
regulates the expression of a number of miRs, including the
miR-17-92 cluster, miR-22, miR-26a, and miR-29b [30,31].
On the other hand, the expression and function of MYC may
in turn be regulated by miRs. For instance, miR-196b has
been recently shown to down-regulate the overamplified the
c-MYC gene in B-cell ALL [32]. It is likely that
downregulation of miR-146b-5p and miR-320d in
DLBCLs is related to loss of function of the MYC gene.
Another notable observation of this study is that miR-320d
is expressed at remarkably higher levels in DLBCLs of the
GCB type than those of the non-GCB type, but further
studies are needed to determine whether the varying
expression of miR-320d is of assistance in differentiating
DLBCLs of various immunophenotypes.
In summary, we have found in this study that low
expression of miR-146b-5p and/or miR-320d may be a
useful biomarker to predict compromised responses of
DLBCL patients to treatment with the CHOP regimen and
that this is associated with the inhibitory effect of these
miRs on DLBCL cell proliferation. Prospective studies
in larger cohorts of DLBCL samples are warranted to
further consolidate the practical significance of low
expression of these miRs in decision making in the
treatment of DLBCLs.Acknowledgments
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